|
- 现金
- 111 元
- 精华
- 0
- 帖子
- 85
- 注册时间
- 2012-4-30
- 最后登录
- 2012-7-17
|
本帖最后由 刀木 于 2012-5-16 20:16 编辑
我父亲由于要做介入，目前停用多吉美，所以有时间研究下这个药物的一些信息。供战友参考。目前我也不能决定究竟吃正版还是印度版的，主要是还在学习2种药究竟区别在哪里。目前从维基百科上查到，生产多吉美的公司是Bayer和Cipla，所以理论上说，这两个公司的药物应该是一样的。
正版价格为半个月量约25000RMB；
以下价格为网上找到的价格，应该算比较靠谱的。
英文药名: Nexavar (Sorafenib Tablets)
中文药名: 多吉美（索拉非尼片）
 此药品需要处方品牌药生产厂家: Bayer Corp.
| 品牌／普通 | 强度 | 剂量 | 价格(美元） | 价格(人民币） | | 品牌 | 200mg | 112 片 | $6589.99 | ￥43,493.93 | | 普通 | 200mg | 120 片 | $1268.89 | ￥8,374.67 | | 普通 | 200mg | 30 片 | $389.99 | ￥2,573.93 | |
在另外一个网站上找到不同的价格。理论上说，印度版多吉美价格优势非常明显。
| Product | Manufacturer | Dosage | Quantity | Price | |  [td]Generic Sorafenib | Cipla (IN) | 200mg | 30 capsules | $550.00 | | | [td]Generic Sorafenib | Cipla (IN) | 200mg | 60 capsules | $999.00 | | | [td]Generic Sorafenib | Cipla (IN) | 200mg | 90 capsules | $1,450.00 | | | [td]Generic Sorafenib | Cipla (IN) | 200mg | 120 capsules | $1,800.00 | | | [td]Generic Sorafenib | Cipla (IN) | 200mg | 150 capsules | $2,250.00 | | | [td]Generic Sorafenib | Cipla (IN) | 200mg | 180 capsules | $2,500.00 | | | [td]Nexavar | Bayer (TR) | 200mg | 112 tablets | $4,999.00 | | | [td]Nexavar | Bayer (TR) | 200mg | 224 tablets | $9,500.00 | | | [td]Nexavar | Bayer (TR) | 200mg | 336 tablets | $14,000.00 | | | [td]Nexavar | Bayer (TR) | 200mg | 448 tablets | $18,000.00 | |
又有空研究了下，发现以下2则消息：
Natco Pharma files India's first compulsory licence plea
Khomba Singh, ET Bureau
Aug 2, 2011, 10.59pm IST
NEW DELHI: Natco Pharma has applied for the country's first compulsory licence to sell a generic version of Bayer's patented medicine, a development whose outcome is expected to determine how global drug makers price their costly drugs in India.
In compulsory licensing, the government allows a generic firm to produce a patented product without the consent of the patent owner. It is one of the flexibilities on patent protection included in the WTO's agreement on intellectual property -TRIPS (trade-related aspects of intellectual property rights) Agreement
| Natco to sell Bayer-patented cancer drug Nexavar | | Patent office upholds challenge, invokes compulsory licensing rule for first time | | BS Reporter / Hyderabad/ New Delhi Mar 13, 2012, 00:40 IST |
In a first-of-its-kind move, a government agency has invoked the compulsory licensing (CL) provision of the Patents Act to allow Hyderabad-based Natco Pharma to sell its generic version of German multinational Bayer’s patent-protected cancer medicine, Nexavar (sorafenib tosylate), at a fraction of the cost of the latter drug in India.
The Controller General of Patents, Designs and Trademarks has asked Natco to manufacture and sell its sorafenib at Rs 8,880 (for a month’s treatment), after paying six per cent royalty on the net sales to Bayer on a quarterly basis. Bayer’s Nexavar costs Rs 284,428 for a month’s dose. The CL is valid till the patent for Nexavar expires in 2021.
The order also wants Natco to supply the medicine free of cost to at least 600 needy and deserving patients every year. The CL, however, restricts Natco from exporting or outsourcing the production of the medicine. It also gives strict instructions to Natco to distinguish its product from Bayer’s product.
意思是，其实理论上印度版多吉美也是属于正版药，是政府批准的，且符合WTO的贸易规则的。
以上信息供战友参考。
|
|
发表于 2012-5-14 22:51
